ESMO Advanced Course on Locoregional and Systemic Therapy Options for Advanced HCC Patients: Optimising Practice and Research

PROGRAMME

ESMO ADVANCED COURSE

SINGAPORE
4-5 DECEMBER 2023

Co-Chairs
Li-Tzong Chen, Taiwan
Arndt Vogel, Germany
ESMO ADVANCED COURSE PROGRAMME
Locoregional and systemic therapy options for advanced HCC patients: Optimising practice and research
Singapore
4-5 December 2023

CO-CHAIRS
Li-Tzong Chen, Taiwan
Arndt Vogel, Germany

SPEAKERS
Chiun Hsu, Taiwan
Rachel W.-J. Jeng, Taiwan
Masaki Kaibori, Japan
Joycelyn J. X. Lee, Singapore
Tim Meyer, United Kingdom
Maria Reig, Spain
Anna Saborowski, Germany
Gonzalo Sapisochin, Canada

LEARNING OBJECTIVES

- To decide between local and systemic therapy or combinations
- To decide about first and second line systemic therapy
- To learn about future targets and clinical trial designs

ACCREDITATION

The programme of this event has been accredited with 9 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

AstraZeneca

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org
Welcome and introduction
Li-Tzong-Chen, TW
Arndt Vogel, DE

Session 1 - Resection and transplantation in HCC
Chair: Li-Tzong Chen, TW

20’ Open vs. laparoscopic resections: What needs to be considered
Masaki Kaibori, JP
20’ Liver transplantation: How far can we go beyond Milan?
Gonzalo Sapsochin, CA
15’ Discussion

Session 2 - Intra-arterial therapies
Chairs: Arndt Vogel, DE and Tim Meyer, UK

20’ Update on SIRT/Y-90
Joycelyn J. X. Lee, SG
20’ Update on TACE
Tim Meyer, UK
20’ Combination of TACE/Y-90 with IO based combinations
Maria Reig, ES
15’ Discussion

Coffee break

Session 3 - Systemic therapies
Chairs: Li-Tzong Chen, TW and Rachel W.-J. Jeng, TW

20’ Update 1st line therapies
Anna Saborowski, DE
20’ Update 2nd line therapies Which 2L treatment after 1L IO-based therapy?
Chiu Hsu, TW
15’ Discussion

Lunch

Session 4 - Precision medicine in HCC
Chairs: Joycelyn J. X. Lee, SG and Anna Saborowski, DE

20’ Role of next generation sequencing and targeted therapies in HCC
Arndt Vogel, DE
20’ Update on molecular classes and clinical biomarkers in HCC: Does HCC of viral vs. metabolic aetiology respond differently to systemic therapy?
Rachel W.-J. Jeng, TW
15’ Discussion

Coffee break
15:10-16:05  **Session 5 - Multidisciplinary approach in advanced HCC**  
Chairs: Arndt Vogel, DE, Maria Reig, ES and Gonzalo Sapisochin, CA  

20’  Systemic review of study design and available results  
Chiu Hsu, TW  

20’  East meets West in practice  
Li-Tzong Chen, TW  

15’  Discussion  

19:00  **Networking dinner**  

---  

**Tuesday, 5 December 2023**  

09:00-12:30  **Workshop sessions**  
Three parallel workshop sessions with 20 delegates in each group (delegates will attend all sessions on a rotation basis)  

25’  Introduction based on clinical cases presented by speakers  

30’  Discussion  

5’  Break  

**Workshop 1**  
**Local and systemic therapy or combinations**  
Joycelyn J. X. Lee, SG  
Tim Meyer, UK  
Gonzalo Sapisochin, CA  

**Workshop 2**  
**First and second line systemic therapy**  
Li-Tzong Chen, TW  
Anna Saborowski, DE  

**Workshop 3**  
**Future targets and clinical trial designs**  
Chiu Hsu, TW  
Maria Reig, ES  
Arndt Vogel, DE  

11:00-11:30  **Coffee break**  

11:30-12:30  **Workshops continuation**  

12:30-13:00  **Synthesis and wrap-up**  
Li-Tzong-Chen, TW  
Arndt Vogel, DE  

13:00-14:00  **Lunch**